\n
\u201cIt can be challenging to take a tablet or pill each day, and it is even harder when taking multiple medications, perhaps several times per day. Setting alarms, using pill organizers, or creating other reminders may help some patients, but they don’t work for everyone,\u201d<\/strong><\/em> Dr. Krew said.<\/p>\n<\/div>\n\n
He added that failing to take medication as prescribed frequently leads to the exacerbation of symptoms, potentially making it more challenging for a patient to carry out daily tasks, and in severe cases, even leading to hospitalization.<\/p>\n<\/div>\n
\n
The fact that these medications need to be administered by a medical professional is another big plus, Krew believed. \u201cThis often allows for more opportunities for a patient to check in with a healthcare provider about their symptoms,\u201d<\/strong><\/em> he said.<\/p>\n<\/div>\n\n
For some people, the steady medication levels may also help them cope with the side effects that come with it, he added. \u201cIndividuals who notice side effects when their oral medication level peaks in the bloodstream, usually within a couple of hours after taking their oral medication, may benefit from the more consistent blood level offered by long-acting injectable\u00a0antipsychotics,\u201d<\/strong> <\/em>Krew stated.<\/p>\n<\/div>\n\n
<\/h2>\n<\/div>\n\n
Abilify Asimtufii Approval and Cost<\/h2>\n<\/div>\n\n
According to an Otsuka spokesperson, the drug is anticipated to be released in the early months of this summer. Although pricing details are currently unavailable, the company is optimistic that Abilify Asimtufii will be eligible for coverage by commercial insurance.<\/p>\n<\/div>\n
\n
<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"
The latest formulation of Abilify offers a significant advancement over its previous long-acting injectable version, as it now lasts twice as long. This extended-release injectable medication, known as Abilify Asimtufii (aripiprazole), only needs to be administered once every two months. This development was announced by Otsuka and Lundbeck, the pharmaceutical companies responsible for producing the […]<\/p>\n","protected":false},"author":9,"featured_media":5707,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"image","meta":[],"categories":[4],"tags":[1685,1686,33,16,1674,739,162],"yoast_head":"\n
FDA Clears New Long-Lasting Injectable For Schizophrenia And Bipolar Disorder Treatment<\/title>\n \n \n \n \n \n \n \n \n \n \n \n\t \n\t \n\t \n \n \n \n\t \n\t \n\t \n